vs

Side-by-side financial comparison of ALPHA PRO TECH LTD (APT) and CollPlant Biotechnologies Ltd (CLGN). Click either name above to swap in a different company.

ALPHA PRO TECH LTD is the larger business by last-quarter revenue ($13.9M vs $179.0K, roughly 77.4× CollPlant Biotechnologies Ltd). ALPHA PRO TECH LTD runs the higher net margin — 5.0% vs -1869.8%, a 1874.9% gap on every dollar of revenue. On growth, ALPHA PRO TECH LTD posted the faster year-over-year revenue change (0.3% vs -28.1%).

Alpha Pro Tech Ltd is a leading developer, manufacturer and marketer of disposable protective apparel, face masks, and building supply products including weather-resistant barriers. It primarily serves the healthcare, industrial, and construction sectors, with core operating markets concentrated in North America.

CollPlant Biotechnologies Ltd is a regenerative medicine company focused on developing and commercializing advanced products using its proprietary plant-derived human collagen technology. Its core offerings cover wound care, soft tissue repair, and aesthetic medicine solutions, targeting key markets across North America, Europe, and Israel, serving healthcare providers in dermatology, orthopedics and cosmetic care segments.

APT vs CLGN — Head-to-Head

Bigger by revenue
APT
APT
77.4× larger
APT
$13.9M
$179.0K
CLGN
Growing faster (revenue YoY)
APT
APT
+28.4% gap
APT
0.3%
-28.1%
CLGN
Higher net margin
APT
APT
1874.9% more per $
APT
5.0%
-1869.8%
CLGN

Income Statement — Q4 2025 vs Q2 2025

Metric
APT
APT
CLGN
CLGN
Revenue
$13.9M
$179.0K
Net Profit
$698.0K
$-3.3M
Gross Margin
37.1%
-3.9%
Operating Margin
6.9%
-1775.4%
Net Margin
5.0%
-1869.8%
Revenue YoY
0.3%
-28.1%
Net Profit YoY
-17.6%
20.5%
EPS (diluted)
$0.06
$0.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
APT
APT
CLGN
CLGN
Q4 25
$13.9M
Q3 25
$14.8M
Q2 25
$16.7M
$179.0K
Q1 25
$13.8M
Q4 24
$13.8M
Q3 24
$14.3M
Q2 24
$16.3M
$249.0K
Q1 24
$13.5M
Net Profit
APT
APT
CLGN
CLGN
Q4 25
$698.0K
Q3 25
$976.0K
Q2 25
$1.2M
$-3.3M
Q1 25
$613.0K
Q4 24
$847.0K
Q3 24
$862.0K
Q2 24
$1.6M
$-4.2M
Q1 24
$576.0K
Gross Margin
APT
APT
CLGN
CLGN
Q4 25
37.1%
Q3 25
39.7%
Q2 25
36.8%
-3.9%
Q1 25
39.0%
Q4 24
37.6%
Q3 24
38.5%
Q2 24
42.0%
-115.3%
Q1 24
40.2%
Operating Margin
APT
APT
CLGN
CLGN
Q4 25
6.9%
Q3 25
7.4%
Q2 25
8.0%
-1775.4%
Q1 25
3.3%
Q4 24
4.9%
Q3 24
5.2%
Q2 24
10.5%
-1769.5%
Q1 24
2.4%
Net Margin
APT
APT
CLGN
CLGN
Q4 25
5.0%
Q3 25
6.6%
Q2 25
7.5%
-1869.8%
Q1 25
4.4%
Q4 24
6.1%
Q3 24
6.0%
Q2 24
10.1%
-1690.8%
Q1 24
4.3%
EPS (diluted)
APT
APT
CLGN
CLGN
Q4 25
$0.06
Q3 25
$0.09
Q2 25
$0.12
$0.28
Q1 25
$0.06
Q4 24
$0.07
Q3 24
$0.08
Q2 24
$0.15
$0.37
Q1 24
$0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
APT
APT
CLGN
CLGN
Cash + ST InvestmentsLiquidity on hand
$17.0M
$11.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$62.5M
$12.5M
Total Assets
$74.1M
$17.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
APT
APT
CLGN
CLGN
Q4 25
$17.0M
Q3 25
$17.7M
Q2 25
$14.5M
$11.4M
Q1 25
$13.4M
Q4 24
$18.6M
Q3 24
$18.4M
Q2 24
$16.2M
$18.9M
Q1 24
$18.5M
Stockholders' Equity
APT
APT
CLGN
CLGN
Q4 25
$62.5M
Q3 25
$62.5M
Q2 25
$62.2M
$12.5M
Q1 25
$61.7M
Q4 24
$62.2M
Q3 24
$62.1M
Q2 24
$62.0M
$20.7M
Q1 24
$61.6M
Total Assets
APT
APT
CLGN
CLGN
Q4 25
$74.1M
Q3 25
$73.9M
Q2 25
$73.2M
$17.4M
Q1 25
$72.2M
Q4 24
$73.7M
Q3 24
$73.3M
Q2 24
$72.7M
$26.6M
Q1 24
$72.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
APT
APT
CLGN
CLGN
Operating Cash FlowLast quarter
$318.0K
Free Cash FlowOCF − Capex
$51.0K
FCF MarginFCF / Revenue
0.4%
Capex IntensityCapex / Revenue
1.9%
Cash ConversionOCF / Net Profit
0.46×
TTM Free Cash FlowTrailing 4 quarters
$1.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
APT
APT
CLGN
CLGN
Q4 25
$318.0K
Q3 25
$3.9M
Q2 25
$2.1M
Q1 25
$-4.0M
Q4 24
$2.4M
Q3 24
$5.3M
Q2 24
$-873.0K
Q1 24
$-1.2M
Free Cash Flow
APT
APT
CLGN
CLGN
Q4 25
$51.0K
Q3 25
$3.8M
Q2 25
$1.9M
Q1 25
$-4.1M
Q4 24
$970.0K
Q3 24
$3.2M
Q2 24
$-1.0M
Q1 24
$-1.3M
FCF Margin
APT
APT
CLGN
CLGN
Q4 25
0.4%
Q3 25
25.9%
Q2 25
11.7%
Q1 25
-29.6%
Q4 24
7.0%
Q3 24
22.3%
Q2 24
-6.2%
Q1 24
-9.3%
Capex Intensity
APT
APT
CLGN
CLGN
Q4 25
1.9%
Q3 25
0.7%
Q2 25
0.8%
Q1 25
1.0%
Q4 24
10.4%
Q3 24
15.1%
Q2 24
0.8%
Q1 24
0.6%
Cash Conversion
APT
APT
CLGN
CLGN
Q4 25
0.46×
Q3 25
4.02×
Q2 25
1.68×
Q1 25
-6.46×
Q4 24
2.85×
Q3 24
6.18×
Q2 24
-0.53×
Q1 24
-2.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons